AstraZeneca’s EUR 135 Million Investment in France
On January 21st, 2019, AstraZeneca inaugurated the extension of the group’s industrial site in the city of Dunkirk in Northern France. The launch was attended by Secretary of State to…
Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.
Conscious of the importance of strategically aligning our company with patient needs, our R&D efforts are focused on contributing to bringing new medicines to market for patients with serious diseases whose treatment options are limited or non-existent.Our rigorous drug discovery and development process, and our commitment to improving health through innovation, have resulted in the creation of a pipeline dedicated to areas where we can lead and make a significant impact.
Our lead pipeline product Elafibranor (GFT505) has recently completed a positive Phase 2b study in NASH (Non-Alcoholic Steato-Hepatitis) and is currently launching a Phase 3 study. This metabolism-related liver disease, which can progress to cirrhosis and even liver cancer, shows a dramatically increasing prevalence worldwide. Elafibranor represents a major hope for patients and their physicians, who currently have no efficient treatment for NASH.
In addition to Elafibranor, our R&D pipeline relies mainly on our world-renowned scientific expertise in gene regulation and nuclear receptors.
It is comprised of multiple drug candidate research programs targeting novel mechanisms of action including the inhibition of RORγ-t.
GENFIT Headquarters
Parc Eurasanté
885, Avenue Eugène Avinée
59120 Loos
France
+33 (0)3 20 16 40 00
On January 21st, 2019, AstraZeneca inaugurated the extension of the group’s industrial site in the city of Dunkirk in Northern France. The launch was attended by Secretary of State to…
Franck Puget, managing director for CSL Behring in France, discusses the blood plasma specialist’s commitment to France, building bridges with public authorities, and regulatory attitudes towards rare disease treatments. …
Guillaume El Glaoui, co-founder and CEO of Laboratoires Majorelle, discusses what spurred the creation of the company, its success of gaining the first reimbursement ever of a condom in France,…
Eric Goupil, CEO of Unither Pharmaceuticals, discusses the company’s development strategy moving forward after the completion of a leveraged buyout in 2017. Additionally, Goupil shares the CDMO’s innovation capabilities as…
Mathilde Lignot-Leloup, director of the French Social Security, provides a fascinating look into the French social system and speaks about its ongoing transformation. She elaborates on change management processes within…
Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also…
Pascal Joly, general manager of Medac France, explains how he and his executive team have built the French affiliate from scratch, while highlighting the importance of gaining swift market access…
Guy Maugis, president of the Franco-German Chamber of Commerce and Industry, explains the impact of the Macron government on the attractiveness of France as well as the importance of a…
Philippe Truelle, President of CDM Lavoisier, highlights the financial impact of the EU’s Falsified Medicines Directive (FMD) on SMEs across Europe and explains how France is becoming increasingly attractive to…
Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to…
In this exclusive interview, David Loew, executive vice president of Sanofi Pasteur, discusses the future of vaccines in France and the rest of the world, their strategic role in reducing…
Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the…
See our Cookie Privacy Policy Here
